Juan Antonio Virizuela

Author

Also Known As

J A Virizuela, J Antonio Virizuela, J. A. Virizuela, J. Virizuela, J.A. Virizuela, Juan A. Virizuela, Juan Antonio Virizuela, Juan Antonio virizuela, Juan Virizuela

113

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario Virgen Macarena Complejo Hospitalario Universitario de Santiago Hospital Universitario Son Espases Hospital Universitario La Paz Hospital General Universitario Gregorio Marañón

About

Juan Antonio Virizuela is an author at Hospital Universitario Virgen Macarena specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	954
2	Engineering	1	1	50
3	Health Sciences	1	1	38
4	Public Health	1	1	21
5	Cell Biology	1	1	17

Juan Antonio Virizuela

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer Noel W. Clarke, Andrew J. Armstrong, Antoine Thiery-Vuillemin, NEJM Evidence UrologyGenitourinary CancerMedicineOlaparib ArmPolymerase Inhibitor Olaparib	2022	357
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial Aleix Prat, Cristina Saura, Tomás Pascual, The Lancet Oncology Breast OncologyMedicinePharmacologyGynecologyBreast Cancer	2019	191
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial Marco Colleoni, Weixiu Luo, Per Karlsson, The Lancet Oncology Breast OncologyMedicineCancer ManagementGynecologyBreast Cancer	2017	120
SEOM clinical guidelines on nutrition in cancer patients (2018) R. de las Peñas, Margarita Majem, Javier Pérez-Altozano, Clinical & Translational Oncology	2019	110
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study Yolanda Escobar, Gerardo Cajaraville, Juan Antonio Virizuela, Supportive Care in Cancer	2015	79
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06) Joaquim Bellmunt, José Trigo, Emiliano Calvo, The Lancet Oncology Multitargeted Chemo-switch RegimenUrologyGenitourinary CancerMedicineMetronomic Therapy	2010	65
SEOM Clinical Guideline for bone metastases from solid tumours (2016) Cristina Grávalos, César A. Rodríguez, Adriano de Paula Sabino, Clinical & Translational Oncology Bone IrradiationSurgical OncologyEngineeringOsteoporosisOrthopaedic Surgery	2016	50
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER) Joan Albanell, María Teresa Martínez, Manuel Ramos, European Journal of Cancer	2021	50
Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial. Juan Francisco Rodríguez-Moreno, Guillermo de Velasco, Inmaculada Fernández, Journal of Clinical Oncology Molecular CharacterizationUrologySurgical OncologyCisplatin-based ChemotherapyHrd Tumor	2020	43
Treatment of cancer pain: Spanish Society of Medical Oncology (SEOM) recommendations for clinical practice Juan Antonio Virizuela, Yolanda Escobar, Javier Cassinello, Clinical & Translational Oncology Pain TherapyPain ResearchHealth SciencesMedicinePain Medicine	2012	38

Page 1